Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The mucin–mucin self-interface refers to the biochemical and physical contact points between individual mucin glycoproteins, primarily MUC5AC and MUC5B, which facilitate the formation of a complex, viscoelastic gel network (Thornton et al., 2008). This interface is maintained through a combination of covalent disulfide bonds between cysteine-rich D-domains and various non-covalent interactions, including hydrophobic and electrostatic forces (Fahy & Dickey, 2010). In healthy individuals, this gel-forming process is essential for mucociliary clearance and protecting the underlying epithelium from pathogens and irritants (Boucher, 2019). However, in respiratory diseases such as cystic fibrosis and COPD, hyper-polymerization or dehydration leads to pathologically thick mucus that obstructs airways (Ridley et al., 2014). Therapeutic strategies targeting this interface aim to disrupt these interactions using mucolytic agents, such as thiol-based reducers, to decrease mucus viscosity and enhance clearance (Henke, 2010). By breaking the bonds at the self-interface, these drugs help restore normal airway patency and reduce the risk of chronic infection and inflammation (Ehre et al., 2019).
Reduction of intermolecular disulfide bonds and disruption of non-covalent interactions between mucin monomers to decrease mucus viscosity (Henke, 2010; Boucher, 2019).
4 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Mucin–mucin self-interface.